Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Baidu, Inc.
  6. News
  7. Summary
    BIDU   US0567521085


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

11/22/2021 | 07:09am EST
Sanofi logo is seen in Paris

BEIJING (Reuters) - Chinese tech giant Baidu Inc said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.

Sanofi had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech/Pfizer and Moderna in developing mRNA shots against COVID-19.

Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.

The French group said https://www.sanofi.com/en/our-covid-19-vaccine-candidates/mrna-vaccine it would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.

Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.

"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market," Huang told Reuters. He declined to disclose the size of the deal.

An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.

Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.

Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests https://arxiv.org/abs/2004.10177, which haven't gone through peer-review.

(Reporting by Roxanne Liu and Ryan Woo; Editing by Simon Cameron-Moore)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BAIDU, INC. 1.29% 150.97 Delayed Quote.1.47%
SANOFI 1.95% 90.25 Real-time Quote.1.89%
All news about BAIDU, INC.
01/25Baidu, Geely Pump $400 Million More into Jidu Automotive Smart Car JV
01/25Baidu Research Sees ‘Large-scale Pre-training Model' as Top Tech Trend in 2022
01/25Baidu's electric vehicle arm Jidu raises $400 million in new funding round
01/24TRACKINSIGHT : Chinese Internet ETF aiming for another blockbuster year
01/20ADRs Close Mostly Lower; Chinese Companies Traded Actively
01/20Will the first metaverse be Chinese?
01/20China Denies Issuing New Investment Guidelines for Tech Companies
01/18Baidu Launches Digital Avatar Platform in Metaverse Push
01/17SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baidu..
01/17Nomura Adjusts Baidu's Price Target to $167 From $184, Says Q1 'Outlook Hurt by Macro;'..
More news
Analyst Recommendations on BAIDU, INC.
More recommendations
Sales 2021 124 B 19 590 M 19 590 M
Net income 2021 14 262 M 2 256 M 2 256 M
Net cash 2021 125 B 19 729 M 19 729 M
P/E ratio 2021 33,2x
Yield 2021 -
Capitalization 332 B 52 546 M 52 568 M
EV / Sales 2021 1,68x
EV / Sales 2022 1,43x
Nbr of Employees 41 000
Free-Float 74,4%
Duration : Period :
Baidu, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAIDU, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 34
Last Close Price 954,99 CNY
Average target price 1 423,06 CNY
Spread / Average Target 49,0%
EPS Revisions
Managers and Directors
Yan Hong Li Chairman & Chief Executive Officer
Rong Luo Chief Financial Officer
Hai Feng Wang Chief Technology Officer
Cui Shanshan Senior VP-Human Resources & Administration
Ji An Ding Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BAIDU, INC.1.47%51 878
ALPHABET INC.-12.37%1 733 714
YANDEX N.V.-28.73%15 234
SOGOU INC.9.82%3 471